OncoCyte Corporation (OCX)
Largest Insider Buys in Sector
OCX Stock Price History Chart
OCX Stock Performance
About OncoCyte Corporation
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Insider Activity of OncoCyte Corporation
Over the last 12 months, insiders at OncoCyte Corporation have bought $7.17M and sold $0 worth of OncoCyte Corporation stock.
On average, over the past 5 years, insiders at OncoCyte Corporation have bought $13.48M and sold $10.9M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BROADWOOD PARTNERS, L.P. (10 percent owner) — $21.17M. Arno Andrew (director) — $299,997. Riggs Josh (CEO and President) — $10,001.
The last purchase of 2,420,000 shares for transaction amount of $7.06M was made by BROADWOOD PARTNERS, L.P. (10 percent owner) on 2024‑04‑11.
List of Insider Buy and Sell Transactions, OncoCyte Corporation
| 2024-04-11 | BROADWOOD PARTNERS, L.P. | 10 percent owner | 2.42M 28.8149% | $2.92 | $7.06M | -8.08% | ||
| 2024-04-11 | Arno Andrew | director | 33,898 0.4083% | $2.95 | $99,999 | -8.08% | ||
| 2024-04-11 | Riggs Josh | CEO and President | 3,390 0.0408% | $2.95 | $10,001 | -8.08% | ||
| 2023-06-14 | KINGSLEY ALFRED D | director | 30,000 0.0246% | $0.21 | $6,447 | -30.23% | ||
| 2023-04-05 | PURA VIDA INVESTMENTS, LLC | 10 percent owner | 663,000 0.6681% | $0.30 | $200,027 | -37.96% | ||
| 2023-04-03 | BROADWOOD PARTNERS, L.P. | 10 percent owner | 26.83M 23.0078% | $0.30 | $8.09M | -47.13% | ||
| 2022-12-23 | Arno Andrew | director | 250,000 0.2087% | $0.35 | $87,875 | -43.42% | ||
| 2022-12-23 | Gutfreund John Peter | director | 75,000 0.0587% | $0.33 | $24,728 | -43.42% | ||
| 2022-12-22 | KINGSLEY ALFRED D | director | 25,000 0.0218% | $0.28 | $7,125 | -27.12% | ||
| 2022-08-17 | Last Andrew J. | 20,000 0.0168% | $0.87 | $17,400 | -58.47% | |||
| 2022-08-17 | Arno Andrew | 7,500 0.0065% | $0.90 | $6,750 | -58.47% | |||
| 2022-08-16 | ANDREWS RONALD ASBURY | President & CEO | 40,000 0.0353% | $0.96 | $38,400 | -59.93% | ||
| 2022-08-15 | KINGSLEY ALFRED D | 5,000 0.0042% | $0.97 | $4,850 | -61.86% | |||
| 2022-08-15 | Arno Andrew | 115,523 0.0974% | $0.97 | $112,057 | -61.86% | |||
| 2022-08-15 | Carter Jennifer L. | 10,500 0.0087% | $0.95 | $9,975 | -61.86% | |||
| 2022-08-15 | GRIFFITH MELINDA | 10,000 0.0087% | $1.00 | $10,000 | -61.86% | |||
| 2022-08-15 | Gutfreund John Peter | 25,000 0.0202% | $0.93 | $23,250 | -61.86% | |||
| 2022-06-24 | Sale | Kamen Efrem | 12,517 0.0114% | $1.05 | $13,160 | -58.04% | ||
| 2022-05-18 | Sale | Yu Li | VP Cntrllr/Prncpl Acctng Offcr | 8,128 0.0072% | $1.14 | $9,266 | -57.89% | |
| 2022-04-14 | BROADWOOD PARTNERS, L.P. | 10 percent owner | 0 – | $0 | $0 | -40.24% |
Insider Historical Profitability
| BROADWOOD PARTNERS, L.P. | 10 percent owner | 4929066 607.4664% | $2.64 | 12 | 0 | +2.24% |
| Arno Andrew | director | 69054 6.4407% | $2.64 | 6 | 0 | <0.0001% |
| Riggs Josh | CEO and President | 3505 0.0424% | $2.64 | 1 | 0 | |
| BROADWOOD CAPITAL INC | 23353697 282.7064% | $2.64 | 1 | 0 | <0.0001% | |
| Kamen Efrem | 8520146 103.14% | $2.64 | 1 | 1 | <0.0001% | |
| PURA VIDA INVESTMENTS, LLC | 10 percent owner | 8090202 97.9353% | $2.64 | 2 | 0 | <0.0001% |
| Lineage Cell Therapeutics, Inc. | 6041154 73.1307% | $2.64 | 0 | 3 | ||
| KINGSLEY ALFRED D | director | 469111 5.6788% | $2.64 | 3 | 3 | <0.0001% |
| ANDREWS RONALD ASBURY | President & CEO | 333212 4.0337% | $2.64 | 8 | 0 | +1.07% |
| Redmond Cavan M. | 110863 1.342% | $2.64 | 2 | 0 | <0.0001% | |
| Levine Mitchell S | Chief Financial Officer | 87080 1.0541% | $2.64 | 5 | 0 | +40.15% |
| Gutfreund John Peter | director | 75000 0.9079% | $2.64 | 2 | 0 | <0.0001% |
| Last Andrew J. | 70170 0.8494% | $2.64 | 2 | 0 | <0.0001% | |
| Carter Jennifer L. | 30500 0.3692% | $2.64 | 1 | 0 | <0.0001% | |
| GRIFFITH MELINDA | 30000 0.3632% | $2.64 | 1 | 0 | <0.0001% | |
| Ross Douglas T. | Chief Scientific Officer | 20317 0.2459% | $2.64 | 1 | 0 | <0.0001% |
| Yu Li | VP Cntrllr/Prncpl Acctng Offcr | 16872 0.2042% | $2.64 | 0 | 1 | |
| Paulsen Gisela | Chief Operating Officer | 16500 0.1997% | $2.64 | 2 | 0 | <0.0001% |
| KALAJIAN TONY T | Sr.VP/Chief Accounting Officer | 15000 0.1816% | $2.64 | 2 | 0 | +163.52% |
| Parker Albert P | Chief Operating Officer | 5000 0.0605% | $2.64 | 1 | 0 | +163.52% |
| ANNETT WILLIAM | President and CEO | 3500 0.0424% | $2.64 | 1 | 0 | <0.0001% |
| HESTERBERG LYNDAL K. | Sr VP, Research & Development | 874 0.0106% | $2.64 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Awm Investment Company Inc | $2.21M | 5.64 | 754,286 | 0% | +$0 | 0.33 | |
| Defender Capital | $163,743.00 | 0.42 | 55,885 | -22% | -$46,191.44 | 0.06 |